Get the Stockscreener App
0.565
8.73%
-0.0663
Abvc Biopharma Inc stock is traded at $0.565, with a volume of 178.59K.
It is down -8.73% in the last 24 hours and down -7.07% over the past month.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
See More
Previous Close:
$0.6313
Open:
$0.63
24h Volume:
178.59K
Relative Volume:
1.39
Market Cap:
$7.03M
Revenue:
$152.40K
Net Income/Loss:
$-10.52M
P/E Ratio:
-0.1456
EPS:
-3.88
Net Cash Flow:
$-4.26M
1W Performance:
-18.00%
1M Performance:
-7.07%
6M Performance:
-46.65%
1Y Performance:
-50.75%
1-Day Range:
$0.55
$0.636
1-Week Range:
$0.55
$0.77
52-Week Range:
$0.4053
$2.45
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Abvc Biopharma Inc Stock (ABVC) Latest News
ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb - MSN
ABVC BioPharma secures additional licensing fees - Investing.com
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - The Manila Times
ABVC BioPharma secures additional licensing fees By Investing.com - Investing.com UK
ABVC BioPharma switches to new independent accounting firm - Investing.com
ABVC BioPharma switches to new independent accounting firm By Investing.com - Investing.com UK
ABVC BioPharma Inc (ABVC) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest - Defense World
Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World
1832 Asset Management L.P. Has $21.08 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Lowers Position in Abbott Laboratories (NYSE:ABT) - MarketBeat
Avidity Biosciences initiated with a Buy at Goldman Sachs - TipRanks
ABB unveils number of investors with maximum and minimum stakes in shares - Trend News Agency
ABB (NYSE:ABBNY) Stock Price Passes Above 200 Day Moving Average of $52.74 - MarketBeat
Rhumbline Advisers Sells 495,177 Shares of Ambev S.A. (NYSE:ABEV) - Defense World
Abans Holdings shares: Aditya Birla Money estimates small-cap stock to give multibagger returns. Buy or avoid? | Stock Market News - Mint
ABB (NYSE:ABBNY) Shares Cross Above 200 Day Moving Average of $52.74 - Defense World
Abbott Laboratories (NYSE:ABT) Shares Up 0.3% - MarketBeat
Bank of Montreal Can Trims Stock Holdings in Abbott Laboratories (NYSE:ABT) - Defense World
J. Stern & Co. LLP Has $30.67 Million Position in Abbott Laboratories (NYSE:ABT) - Defense World
Abbott Laboratories (NYSE:ABT) Shares Acquired by Frank Rimerman Advisors LLC - Defense World
ABEV’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Xponance Inc. Has $24.89 Million Position in Abbott Laboratories (NYSE:ABT) - Defense World
Abans Holdings Limited gets buy call with target price of Rs 710 | Check details here - India.com
Asset Management Firm Abans Holdings Gets Buy Rating from Aditya Birla MoneyKnow Share Price Target - Times Now
DRW Securities LLC Sells 4,279 Shares of Abbott Laboratories (NYSE:ABT) - Defense World
Profund Advisors LLC Sells 114 Shares of Abbott Laboratories (NYSE:ABT) - Defense World
Anheuser-Busch InBev SA/NV (NYSE:BUD) Shares Sold by Davidson Kempner Capital Management LP - Defense World
It makes sense and dollars to buy ArriVent BioPharma Inc. (AVBP) stock - SETE News
Addus HomeCare price target raised to $145 from $140 at Oppenheimer - TipRanks
American Century Companies Inc. Has $9.70 Million Position in Anheuser-Busch InBev SA/NV (NYSE:BUD) - Defense World
AB Capital breaks out from inverse Head & Shoulder pattern; time to buy? - The Economic Times
ProShare Advisors LLC Acquires 127,133 Shares of Abbott Laboratories (NYSE:ABT) - Defense World
Anheuser-Busch InBev SA/NV (NYSE:BUD) Shares Bought by Heron Bay Capital Management - Defense World
Is AbbVie (NYSE:ABBV) A Risky Investment? - Yahoo Finance
ABIVAX Société Anonyme (NASDAQ:ABVX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Huber Capital Management LLC Has $1.62 Million Stock Holdings in Anheuser-Busch InBev SA/NV (NYSE:BUD) - Defense World
Anheuser-Busch InBev SA/NV (NYSE:BUD) Shares Bought by Callan Capital LLC - Defense World
Abbott Laboratories (NYSE:ABT) Shares Purchased by Ensign Peak Advisors Inc - MarketBeat
Anheuser-Busch InBev SA/NV (NYSE:BUD) Stake Increased by Moors & Cabot Inc. - Defense World
XTX Topco Ltd Invests $2.09 Million in Anheuser-Busch InBev SA/NV (NYSE:BUD) - Defense World
Envestnet Asset Management Inc. Has $35.56 Million Position in Anheuser-Busch InBev SA/NV (NYSE:BUD) - Defense World
Ieq Capital LLC Purchases 2,154 Shares of Abbott Laboratories (NYSE:ABT) - Defense World
AbbVie’s Elahere gets CHMP nod as competition advances - BioCentury
Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance
Abbott Laboratories stock outperforms competitors despite losses on the day - MarketWatch
AbbVie (NYSE:ABBV) Trading Down 0.3% - MarketBeat
Abbott Laboratories (NYSE:ABT) Shares Down 0.1% - MarketBeat
Agilent Completes Acquisition of BIOVECTRA – Company Announcement - Financial Times
SYSTM Wealth Solutions LLC Has $117,000 Holdings in Anheuser-Busch InBev SA/NV (NYSE:BUD) - Defense World
Abbvie Slides on ELAHERE Opinion of its Cancer Treatment - Baystreet.ca
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):